PT-141 / Oxytocin / Tesamorelin is a multi-compound research formulation combining three molecules associated with distinct receptor and neuroendocrine signaling systems. The combination provides a controlled format for laboratory investigation involving melanocortin signaling, oxytocin receptor activity, growth hormone-releasing hormone pathways, and interactions among multiple signaling mechanisms.

PT-141, also known as Bremelanotide, is a synthetic cyclic peptide related to the melanocortin peptide family. Research has examined its interactions with melanocortin receptors and the neurological signaling pathways associated with melanocortin receptor activation.

Oxytocin is a naturally occurring nonapeptide that functions as both a hormone and neuropeptide. Laboratory research has investigated its interaction with oxytocin receptors and its role in neuroendocrine signaling, cellular communication, and pathways associated with social and reproductive biology.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Research has examined its interaction with GHRH receptors and the signaling mechanisms associated with pituitary growth hormone release and downstream IGF-1-related pathways.

This formulation combines 10mg PT-141, 3mg Oxytocin, and 10mg Tesamorelin and is supplied in a nasal research format for controlled laboratory investigation involving melanocortin, oxytocin, and GHRH-related signaling.